Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-first-participant-dosed-in-phase-2-study-of-amx0035-for-the-treatment-of-wolfram-syndrome

/by